Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure

Hepatology Research

Volumn 44, Issue 5, 2014, Pages 491-501

  Fujiwara, Keiichi ^a   Yasui, Shin ^a   Yonemitsu, Yutaka ^a   Mikata, Rintaro ^a   Arai, Makoto ^a   Kanda, Tatsuo ^a   Imazeki, Fumio ^a   Oda, Shigeto ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Acute liver failure; Corticosteroid; Fulminant hepatitis; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; LAMIVUDINE; LIVER ENZYME; METHYLPREDNISOLONE;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DUODENUM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS A; HEPATITIS B; HEPATITIS E; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INTESTINAL BLEEDING; JAPANESE; KIDNEY CARCINOMA; LIVER INJURY; LUNG ASPERGILLOSIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UTERUS CANCER; VIRUS INFECTION;

EID: 84899058600     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12148     Document Type: Article

References (31)

1. Mochida S, Takikawa Y, Nakayama N etal. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011; 41: 805-812.
2. Fujiwara K, Yasui S, Tawada A etal. Autoimmune fulminant liver failure in adults. A single Japanese center experience. Hepatol Res 2011; 41: 133-141.
3. Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol 2012; 47: 849-861.
4. Ducci H, Katz R. Cortisone, ACTH and antibiotics in fulminant hepatitis. Gastroenterology 1952; 21: 357-374.
5. Evans AS, Spring H, Nelson RS. Adrenal hormone therapy in viral hepatitis III. The effect of ACTH and cortisone in severe and fulminant cases. Ann Intern Med 1953; 38: 1148-1159.
6. Katz R, Velasco M, Klinger J, Alessandri H. Corticosteroids in the treatment of acute hepatitis in coma. Gastroenterology 1962; 42: 258-265.
7. Ware AJ, Jones RE, Thorey JW, Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 1974; 62: 130-133.
8. Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B. Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients. Medicine (Baltimore) 1969; 48: 151-172.
9. Redeker AG, Schweitzer IL, Yamahiro HS. Randomization of corticosteroid therapy in fulminant hepatitis [Letter]. N Engl J Med 1976; 294: 728-729.
10. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med 1976; 294: 681-687.
11. Randomized trial of steroid therapy in acute liver failure: a report from the European Association for the Study of the Liver. Gut 1979; 20: 620-623.
12. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E, The Acute Hepatic Failure Study Group. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991; 36: 1223-1228.
13. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G, The Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 2008; 38: 646-657.
14. Oketani M, Ido A, Nakayama N etal., The Intractable Hepato-Biliary Diseases Study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 2013; 43: 97-105.
15. Tsubouchi H, Oketani M. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2004). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2006. 61-69. (In Japanese.)
16. Tsubouchi H, Oketani M, Ido A. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2005). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2007. 90-100. (In Japanese.)
17. Tsubouchi H, Oketani M, Ido A. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2006). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2008. 83-94. (In Japanese.)
18. Tsubouchi H, Oketani M, Ido A. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2007). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2009. 83-93. (In Japanese.)
19. Tsubouchi H, Oketani M, Ido A. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2008). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2010. 95-106. (In Japanese.)
20. Tsubouchi H, Oketani M, Ido A. Fulminant hepatitis and late onset hepatic failure (LOHF) in Japan (2009). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare; 2011. 96-113. (In Japanese.)
21. Mochida S, Nakayama N. Acute liver failure and late onset hepatic failure (LOHF) in Japan (2010). Annual Report of the Intractable Hepato-Biliary Diseases Study Group of Japan Supported by the Ministry of Health, Labor, and Welfare. 2012. 101-106. (In Japanese.)
22. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988; 2: 72-74.
23. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-441.
24. Yoshiba M, Sekiyama K, Inoue K, Fujita R. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis. J Gastroenterol 1995; 30: 67-73.
25. Mochida S, Ohno A, Arai M, Fujiwara K. Role of adhesion between activated macrophages and endothelial cells in the development of two types of massive hepatic necrosis in rats. J Gastroenterol Hepatol 1995; 10: S38-42.
26. Sato A, Takikawa Y, Sato S, Suzuki K. Evaluation of effectiveness of glucocorticoid treatment using a rat acute hepatic failure model. Kanzo 1999; 40: 217-226. (In Japanese.)
27. Ryo K, Kamogawa Y, Ikeda I etal. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 2000; 95: 2047-2055.
28. Fujiwara K, Yasui S, Yonemitsu Y etal. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol 2008; 43: 711-719.
29. Kotoh K, Enjoji M, Nakamuta M etal. Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure. World J Gastroenterol 2006; 12: 6678-6682.
30. Naiki T, Nakayama N, Mochida S etal. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: application to indication criteria for liver transplantation. Hepatol Res 2012; 42: 68-75.
31. Lee WM. Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol 2012; 26: 3-16.